JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 102 filers reported holding JUNO THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $3,009,000 | -49.4% | 65,843 | -50.3% | 0.01% | -57.9% |
| Q3 2017 | $5,947,000 | +42.0% | 132,558 | -5.4% | 0.02% | +26.7% |
| Q2 2017 | $4,187,000 | +620.7% | 140,065 | +434.6% | 0.02% | +400.0% |
| Q1 2017 | $581,000 | -81.6% | 26,200 | -84.3% | 0.00% | -76.9% |
| Q4 2016 | $3,150,000 | +204.6% | 167,082 | +384.6% | 0.01% | +160.0% |
| Q3 2016 | $1,034,000 | -45.4% | 34,475 | -30.1% | 0.01% | -44.4% |
| Q2 2016 | $1,894,000 | -21.5% | 49,299 | -22.2% | 0.01% | -30.8% |
| Q1 2016 | $2,413,000 | +169.0% | 63,371 | +210.6% | 0.01% | +160.0% |
| Q4 2015 | $897,000 | +75.2% | 20,400 | +62.1% | 0.01% | +66.7% |
| Q3 2015 | $512,000 | -91.9% | 12,581 | -89.4% | 0.00% | -92.7% |
| Q2 2015 | $6,306,000 | +201.1% | 118,251 | +242.5% | 0.04% | +156.2% |
| Q1 2015 | $2,094,000 | +379.2% | 34,523 | +312.2% | 0.02% | +433.3% |
| Q4 2014 | $437,000 | – | 8,375 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |